Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
H1N1 Vaccine Market Growth Potential: How Will Market Size Shift Through 2030?
The h1n1 vaccine market size has demonstrated significant expansion in recent years. Its value is expected to grow from $3.52 billion in 2025 to $3.78 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.3%. Historically, this market’s growth has been driven by factors such as past h1n1 pandemic outbreaks, extensive government-led mass immunization campaigns, increasing global influenza incidence, dedicated public health funding for vaccines, and the presence of established cold chain infrastructure.
The h1n1 vaccine market is projected to experience substantial expansion over the coming years. It will grow to $5.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. This anticipated growth during the forecast period is fueled by factors such as enhanced pandemic readiness efforts, the escalating susceptibility of the older demographic, broader national immunization programs, improved healthcare accessibility within developing nations, and the continuous threat of influenza virus mutations. Key trends anticipated during the same period involve the enlargement of both seasonal and pandemic influenza immunization campaigns, the growing adoption of intranasal vaccines to boost patient adherence, increased governmental reserves of h1n1 vaccines, improved vaccination rates among children and the elderly, and a heightened emphasis on swift vaccine delivery during disease outbreaks.
Get A Free Sample Report With In-Depth Market Insights:
H1N1 Vaccine Market Development Factors: What’s Supporting Demand?
The increasing occurrence of chronic diseases is anticipated to boost the expansion of the H1N1 vaccine market in the future. These conditions are persistent health issues, typically lasting over three months, demanding continuous medical care or management, encompassing ailments like diabetes, cardiac disease, and arthritis. The growth in chronic diseases is largely attributable to unhealthy lifestyle habits such as inadequate diet, lack of physical activity, and consumption of tobacco or alcohol, which lead to obesity, elevated blood pressure, and other enduring health risks. H1N1 vaccines are vital for safeguarding individuals suffering from chronic diseases, mitigating the likelihood of severe influenza complications and averting the worsening of conditions, hospital admissions, or fatalities within susceptible populations. For example, in June 2024, the National Health Service, a UK-based government department, reported that 3,615,330 individuals registered with a general practitioner (GP) had been diagnosed with non-diabetic hyperglycemia or pre-diabetes (a state characterized by higher-than-normal blood sugar levels, yet not meeting the criteria for diabetes) in 2023, representing an 18% surge from 3,065,825 instances in 2022. Consequently, the growing prevalence of chronic diseases is fueling the development of the H1N1 vaccine market.
H1N1 Vaccine Market Segments: Where Is Growth Concentrated?
The h1n1 vaccine market covered in this report is segmented –
1) By Product Type: Inactivated Vaccine, Live Attenuated Vaccine
2) By Route Of Administration: Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination
3) By End Users: Hospitals, Clinics, Research And Diagnostic Laboratories, Other End Users
Subsegments:
1) By Inactivated Vaccine: Injectable Inactivated Vaccine, Intranasal Inactivated Vaccine
2) By Live Attenuated Vaccine: Injectable Live Attenuated Vaccine, Intranasal Live Attenuated Vaccine
H1N1 Vaccine Market Transformation Trends: What Innovations Are Driving Change?
Leading firms within the H1N1 vaccine market are introducing novel products and innovative solutions, for instance, a unique needle-free nasal vaccine, aiming to maintain their competitive standing. This form of vaccination, a needle-free nasal vaccine, dispenses with conventional needles or syringes. Rather, its administration occurs via a non-invasive, pain-free, and needleless method, predominantly through the nasal passage. As an illustration, during October 2023, Serum Institute, an India-based manufacturer of vaccines, partnered with Mylab, an India-based diagnostic company, to release Nasovac S4. This needle-free nasal influenza vaccine is designed to provide active immunity against influenza resulting from the H1N1 virus and H3N2 virus. It employs strains from the Type A and Type B virus to generate antibodies combating influenza. Nasovac S4 is suitable for all individuals older than the age of 2, assisting in stimulating the immune system’s defense against influenza.
H1N1 Vaccine Market Key Participants And Competitive Landscape
Major companies operating in the h1n1 vaccine market are Sanofi SA, GlaxoSmithKline PLC, CSL Limited, AstraZeneca Inc., Zydus Lifesciences Limited, Merck and Co.Inc., Novavax Inc., Panacea Biotec Ltd., Sinovac Biotech Ltd., Green Cross Corp., Pfizer Inc., Seqirus Ltd., Cipla Inc., Protein Sciences Corporation, Hualan Biological Engineering Inc., Changsheng Bio-Technology Co. Ltd., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Bio Farma Group, PT Kalbe Farma Tbk, Moderna Inc., CureVac NV, BioNTech SE, Inovio Pharmaceuticals Inc., Vaxart Inc., Altimmune Inc., Dynavax Technologies Corporation, VBI Vaccines Inc., GeoVax Labs Inc.
View The Full H1N1 Vaccine Market Report:
H1N1 Vaccine Market Geographic Distribution And Regional Opportunities
North America was the largest region in the H1N1 vaccine market in 2025. The regions covered in the h1n1 vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
